SemBioSys announces first quarter 2008 financial and operation...(us tobegin the clinical trials for our s...)

Date:5/9/2008

us to begin the clinical trials for our safflower-produced insulin, with the initiation of the animal toxicology study required before the submission of an IND. We intend to submit that IND in the coming months and, if granted approval by the FDA, initiate a Phase I/II trial during the second half of 2008," said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "Equally as important as insulin, we have initiated preclinical studies to establish functionality of safflower-produced Apo AI(Milano) in animals, the results of which will be critical in confirming our transformative HDL (high density lipoprotein) program. We also continue to execute our growth strategy for our non-pharmaceutical products. In particular, we have launched our second generation oleosome product, Hydresia(TM) G2, and signed Burt's Bees as our first brand name customer. We continue to develop business opportunities to further increase the sales revenues of Botaneco and are currently in discussions with a number of potential customers in this area."

Financials

Please note that prior to the third quarter of 2007, SemBioSys operated under one segment. During the third quarter of 2007, Botaneco completed the construction of its manufacturing facility and SemBioSys began operating in two reportable segments: (i) the Biopharmaceutical, Animal Health, and Nutritional Oils segment focused on the Company's lead pharmaceutical candidates, recombinant human insulin and Apo AI, in addition to its animal health product, ImmunoSphere(TM) and nutritional oils, DHA and GLA and (ii) the Specialty Ingredients segment which will manufacture and market branded lines of naturally derived base emulsions and delivery systems used in the development of cosmetic, personal care and prescription topical/dermatology products through the Botaneco subsidiaries.

Total revenue for the three-month period ended March 31, 2008 was $210,027 compared with $542,788 for the corresponding period in 2007.
'/>"/>

SOURCE SemBioSys Genetics Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. SemBioSys receives milestone payments from AVAC Ltd.
2. SemBioSys initiates toxicology study for safflower-produced insulin
3. SemBioSys announces 2007 financial and operational results
4. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
5. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
6. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
7. SemBioSys signs option agreement for safflower-produced food ingredient
8. SemBioSys announces 2007 third quarter results
9. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
10. SemBioSys updates Apo AI development program
11. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period